Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 6.44B +251.2% |
| Revenue (ttm) | 51.48M -12.6% |
| Net Income | -315.00M |
| EPS | -3.55 |
| Shares Out | 82.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 604,785 |
| Open | 77.44 |
| Previous Close | 76.91 |
| Day's Range | 75.82 - 80.70 |
| 52-Week Range | 36.65 - 103.00 |
| Beta | 2.03 |
| Analysts | Strong Buy |
| Price Target | 118.55 (+51.54%) |
| Earnings Date | Apr 30, 2026 |
About KYMR
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid... [Read more]
Financial Performance
In 2025, Kymera Therapeutics's revenue was $39.21 million, a decrease of -16.70% compared to the previous year's $47.07 million. Losses were -$311.35 million, 39.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for KYMR stock is "Strong Buy." The 12-month stock price target is $118.55, which is an increase of 51.54% from the latest price.
News
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, In...
Kymera Therapeutics Slides: Corporate presentation
Kymera Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
Penny Carlson will oversee global clinical development operations across Kymera's oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass., June ...
Kymera Therapeutics presents preclinical lupus data for KT-579
Kymera Therapeutics (KYMR) announced the presentation of new preclinical data for KT-579, its potent, selective, oral IRF5 degrader, demonstrating disease-modifying activity in lupus models. In multip...
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models
Kymera Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted progress in targeted protein degradation, with KT-621 advancing in global Phase IIb studies for atopic dermatitis and asthma. Strong operational focus, robust safety data, and regulatory momentum position the pipeline for significant impact.
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...
Kymera Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
KT-621 phase IIb studies in atopic dermatitis and asthma are progressing on schedule, with strong enthusiasm and robust safety data supporting advancement. The pipeline includes promising IRF5 and IRAK4 degraders, with lupus prioritized for proof-of-concept and broader indications under consideration.
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases
Kymera Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Management highlighted progress in targeted protein degradation, focusing on immunology with KT-621 in phase II trials for atopic dermatitis and asthma, and IRF5 in early clinical studies. Differentiation is based on sustained target degradation, with large market opportunities in both adult and pediatric populations. Data readouts for key programs are expected in the next 12–24 months.
Kymera Therapeutics initiated with a Buy at Canaccord
Canaccord analyst Edward Nash initiated coverage of Kymera Therapeutics (KYMR) with a Buy rating and $106 price target
Kymera Therapeutics initiated with a Buy at Canaccord
Canaccord initiated coverage of Kymera Therapeutics (KYMR) with a Buy rating and $106 price target The firm views Kymera as one of the “more cutting-edge technology companies” developing drugs within…
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models
Kymera Therapeutics price target lowered to $119 from $123 at Morgan Stanley
Morgan Stanley analyst Judah Frommer lowered the firm’s price target on Kymera Therapeutics (KYMR) to $119 from $123 and keeps an Overweight rating on the shares. Kymera Therapeutics highlighted conti...
Kymera Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong pipeline progress, with KT-621 advancing in AD and asthma and KT-579 entering phase I. Financially, $34.4M in revenue was recognized, with a $1.55B cash runway into 2029. Gilead exercised its KT-200 option, and key clinical data readouts are expected in 2026–2027.
Kymera Therapeutics Earnings release: Q1 2026
Kymera Therapeutics released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Kymera Therapeutics Quarterly report: Q1 2026
Kymera Therapeutics has published its Q1 2026 quarterly earnings report on April 30, 2026.
Kymera Therapeutics Slides: Q1 2026
Kymera Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Kymera Therapeutics reports Q1 EPS (71c), consensus (86c)
Reports Q1 revenue $34.37M, consensus $8.23M. “As we continue to advance KT-621 and KT-579 through clinical development, our focus remains on disciplined execution and delivering on multiple important...
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to K...
Kymera Therapeutics Proxy statement: Proxy filing
Kymera Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Kymera Therapeutics Proxy statement: Proxy filing
Kymera Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine...